Cervical Cancer Vaccine Market Report 2025

The cervical cancer vaccine market size has grown strongly in recent years. It will grow from $87.36 billion in 2024 to $93.22 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to awareness campaigns and education, government initiatives and vaccination programs, increased incidence of cervical cancer, healthcare provider recommendations, global efforts for women's health.

The cervical cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $126.94 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to expansion of vaccination coverage, integration into routine immunization programs, advancements in hpv testing and screening, global advocacy for hpv vaccination, rising focus on adolescent vaccination. Major trends in the forecast period include incorporation of new adjuvants, integration of digital health platforms, innovative vaccine development, public-private partnerships, educational campaigns and advocacy.

The growth trajectory of the cervical cancer vaccine market is anticipated to surge, propelled by the escalating prevalence of cervical cancer cases. Cervical cancer, affecting the lower part of the uterus known as the cervix, is witnessing an increase in reported cases, primarily attributed to factors such as inadequate Human papillomavirus (HPV) vaccination, poor hygiene practices, and limited awareness and knowledge concerning cervical cancer. Notably, cervical cancer vaccines play a pivotal role in preventing this disease by targeting high-risk types of human papillomavirus (HPV). For example, in January 2023, the American Cancer Society reported 13,960 cases of cervical cancer in the United States alone. Consequently, the rising incidence of cervical cancer cases serves as a driving force behind the growth of the cervical cancer vaccine market.

The increase in healthcare spending is significantly driving the growth of the cervical cancer vaccine market. Healthcare spending, which refers to the total financial resources allocated to the healthcare sector in a particular region or country, plays a vital role in supporting efforts for cervical cancer vaccination. Investment in cervical cancer vaccines aims to prevent the disease's onset and reduce the economic burden linked to treatment costs. Additionally, this strategic allocation of resources is designed to improve overall public health outcomes and promote long-term cost-effectiveness by minimizing the need for extensive medical interventions. For example, in May 2023, a report from the Office for National Statistics, a UK-based government department, noted that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth rate of 0.9% in 2022. In 2023, UK healthcare expenditure reached approximately $317.63 billion (£292 billion). Therefore, the rise in healthcare spending is a key factor driving the expansion of the cervical cancer vaccine market.

Product innovation stands out as a significant and growing trend within the cervical cancer vaccine market, with prominent market players directing their efforts towards the development of pioneering products to reinforce their market positions. An example of this trend occurred in May 2022 when GlaxoSmithKline, a UK-based pharmaceutical company, obtained approval from China's National Medical Products Administration (NMPA) for a two-dose schedule of its vaccine, Cervarix. This vaccine, intended for girls aged nine to fourteen, has been authorized to prevent cervical cancer. This approval marks a significant milestone as Cervarix becomes the first imported HPV vaccine to utilize a two-dose regimen for this specific age group in mainland China.

Major companies engaged in cervical cancer vaccines are strategically focusing on collaboration and partnerships to deliver reliable services to their clientele. These strategic partnerships involve structured alliances between multiple commercial enterprises, typically established through various business agreements or contracts. For instance, in June 2023, Nykode Therapeutics ASA, a Norway-based provider specializing in next-generation vaccines, expanded its collaboration with Roche Holding AG, a Switzerland-based healthcare company, to advance VB10.16, an off-the-shelf therapeutic cancer vaccine. The collaborative effort aims to evaluate VB10.16 in combination with Roche's atezolizumab (Tecentriq), an anti-PD-L1 immunotherapy, in patients diagnosed with advanced cervical cancer. This partnership holds promise in developing a novel and effective treatment option for a type of cancer that has limited treatment alternatives and typically poor prognoses.

In March 2024, Halma PLC, a UK-based technology company, acquired Rovers Medical Devices for €85 million. This acquisition is aimed at enhancing Halma PLC's offerings in the women's health sector, specifically in cervical cancer diagnostics. Rovers Medical Devices is a Netherlands-based manufacturing company that produces the only self-sampling device equipped with built-in features to ensure accurate sample collection and to provide reassurance to women.

Major companies operating in the cervical cancer vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co Inc., GlaxoSmithKline plc, Advaxis Inc., Immunovaccine Inc., AstraZeneca PLC, EpiVax Inc., ImmunoVaccine Technologies Inc., OncoOne, Xynomic Pharmaceuticals, Vaxart Inc., Genentech Inc., Astellas Pharma Inc., MedImmune LLC, Vaxine Pty Ltd, Inovio Pharmaceuticals, Advaxis Inc., ImmunoGen Inc., Gritstone Oncology, Inc., VBI Vaccines Inc., Genexine Inc., Aikido Pharma Inc., BioNTech SE, CureVac AG, Karyopharm Therapeutics, Epigenomics AG, Imugene Limited, Immunicum AB, Targovax ASA.

North America was the largest region in the cervical cancer vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cervical cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cervical cancer vaccine is designed to prevent cervical cancer by targeting high-risk types of human papillomavirus (HPV), the primary cause of most cervical cancer cases. These vaccines stimulate the body's immune response, generating antibodies to recognize and neutralize the HPV virus.

The main cervical cancer vaccines include Cervarix, Gardasil, and Gardasil 9. Cervarix is specifically formulated to protect against certain HPV strains associated with cervical cancer. These vaccines are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, reaching diverse end-users such as hospitals, biotechnology companies, academic and research organizations, among others.

The cervical cancer vaccine market research report is one of a series of new reports that provides cervical cancer vaccine market statistics, including the cervical cancer vaccine industry global market size, regional shares, competitors with a cervical cancer vaccine market share, detailed cervical cancer vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the cervical cancer vaccine industry. This cervical cancer vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cervical cancer vaccine market consists of sales of a gardiquimod, V503, silgard, and Human papillomavirus vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.